In situ magnetite production for selenium and arsenic treatment in diffuse plumes
This technology uses in situ magnetite generation to treat selenium and arsenic in diffuse plumes by oxidizing Fe(II) with nitrate, avoiding conventional reductive pathways. The method effectively retains arsenic under reducing conditions needed for selenium immobilization while ensuring long-term stability against chemical changes.
Overview
This innovative solution addresses the challenge of treating selenium (Se) and arsenic (As) contamination in diffuse plumes by leveraging in situ production of magnetite. Unlike traditional methods that exacerbate arsenic solubilization by creating reducing conditions, this technology employs an oxidative pathway to oxidize Fe(II) with nitrate, resulting in stable magnetite and goethite mineral assemblages. These minerals effectively adsorb arsenic even under conditions required for selenium immobilization, offering a dual benefit.
Technical specifications
- Oxidative Process: Utilizes nitrate to oxidize Fe(II), bypassing conventional methods that use carbon additions.
- Mineral Stability: Results in the formation of magnetite and goethite, which are stable under both reducing and oxidizing conditions.
- Arsenic and Selenium Retention: These minerals retain arsenic and selenium through controlled oxidative dispersion, preventing solubilization.
- Experimental Validation: Conducted through batch and column experiments using materials from contaminated sites, with monitoring by ICPMS and X-ray absorption spectroscopy.
Technology readiness level
The technology is currently at TRL 4, with demonstrated component and/or breadboard validation in laboratory environments. Further testing is planned to optimize conditions in real-world scenarios.
About Columbia University
Columbia University is a comprehensive private research university in New York City, combining an Ivy League academic profile with globally engaged scholarship and professional education. Its integration with a major hospital system through Columbia University Irving Medical Center and NewYork-Presbyterian enables clinical collaboration, access to diverse patient populations, and regulated studies at scale. State-of-the-art laboratories and shared core facilities across the Morningside and Manhattanville campuses support co-located industry projects, while proximity to New York’s finance, media, and healthcare ecosystems streamlines talent pipelines and pilot deployments. Industry engages via sponsored research, affiliate programs, executive education, and convenings that connect faculty expertise with corporate R&D priorities. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, alongside New York State and philanthropic sources. Columbia Technology Ventures provides IP management, licensing, startup support, and translational funding mechanisms that lower barriers to commercialization.
delivered to your inbox.